Key information

🔎 Fund Overview

Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.